Current place of monoamine oxidase inhibitors in the treatment of depression.
about
Treating comorbid anxiety and depression: Psychosocial and pharmacological approachesPharmacology and Clinical Drug Candidates in Redox MedicineTargeting the noradrenergic system for gender-sensitive medication development for tobacco dependenceA brief history of the development of antidepressant drugs: from monoamines to glutamateInhibitors of MAO-A and MAO-B in Psychiatry and NeurologyCombination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depressionBehavioural screening of zebrafish using neuroactive traditional Chinese medicine prescriptions and biological targets.The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatmentTherapeutic Effects of Phytochemicals and Medicinal Herbs on Depression.Gene expression changes consistent with neuroAIDS and impaired working memory in HIV-1 transgenic rats.Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.Early life environmental and pharmacological stressors result in persistent dysregulations of the serotonergic system.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.Evaluation of the Inhibitory Effects of Bavachinin and Bavachin on Human Monoamine Oxidases A and B.Combining Stimulants and Monoamine Oxidase Inhibitors: A Reexamination of the Literature and a Report of a New Treatment Combination.Natural Products Screening for the Identification of Selective Monoamine Oxidase-B Inhibitors.Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters.Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.Monoamine oxidase A and B substrates: probing the pathway for drug development.Monoamine oxidase: radiotracer chemistry and human studies.Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety.Zebrafish models of major depressive disorders.Contribution of Monoamine Oxidase Inhibition to Tobacco Dependence: A Review of the Evidence.Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.Augmentation of phenelzine with aripiprazole and quetiapine in a treatment-resistant patient with psychotic unipolar depression: case report and literature review.Toward a multiscale modeling framework for understanding serotonergic function.Differential protection of black-seed oil on econucleotidase, cholinesterases and aminergic catabolizing enzyme in haloperidol-induced neuronal damage of male rats.Regulatory Pathways of Monoamine Oxidase A during Social Stress.Tranylcypromine Causes Neurotoxicity and Represses BHC110/LSD1 in Human-Induced Pluripotent Stem Cell-Derived Cerebral Organoids Model.Monoamine oxidase inhibitory constituents of propolis: kinetics and mechanism of inhibition of recombinant human MAO-A and MAO-B.The antidepressant tranylcypromine alters cellular proliferation and migration in the adult goldfish brain.
P2860
Q26770334-54B90443-D28C-45EA-BBBF-AA8CDE492113Q26785525-67429568-8D71-4E2D-86B6-15C1B8BAFD29Q26999258-4BA0A978-F764-484E-962C-BBED2D7B110BQ27028050-CA1128C1-3FF2-492D-87EF-CFF95138C963Q28069609-014ABFDC-47C0-4079-B23D-EDCA96425310Q28084183-46307564-64B7-412D-9B2E-34A8A1BD5BFEQ30580754-59F05DA3-F32F-4136-9DB9-88127CD250E7Q33593061-F6EE9629-91DF-4359-B42F-97FF00F183CFQ33630966-C9A05C3F-E4A5-429B-A11B-32FC2F6C0499Q33936233-B32B3E23-9AA2-48D2-96BE-76C6B48B4CD1Q34906855-BC899438-23C6-4753-B334-842556B2072BQ35541020-4CFFFBC8-5B3C-4755-937D-D103A8C4BEA2Q35862776-D43F0D7F-E9E0-42FA-9EDA-AEB0FCB8742CQ36237385-A9095E3B-7C41-463B-96CE-7C2B6073249DQ36722925-3FD616BF-236F-4EBA-86A6-143D0708BBFAQ36983563-D47BA463-E6D8-41E2-99BA-9DF44B05BADCQ37158450-15322EF6-345A-4517-8288-C5D16D53F883Q37279054-3096CA60-F297-427C-9EFF-2A6C8781FAE2Q37552410-F1EA577B-037F-46B2-9897-8E548295B453Q38217505-64BB7966-84D3-43A0-8530-9765FD0E5634Q38354327-DF598EEC-E1E5-4253-A8C8-FC21C9AA3AB6Q38367401-9617C4C5-7E5E-4930-B70E-EC67147484ACQ38603307-20306E66-45D2-45AB-A103-AD144378A6B1Q38617975-582233F8-B603-4BF6-91D8-C2E017B137B9Q38865983-C89C400A-AFDA-4B30-B7B0-92960BCD4D6DQ39048593-39CD2ACD-3B29-4458-BACF-89F9E80D3239Q39247652-F9C98699-D6EC-4C53-AE0F-AFC8C17D088FQ42406412-79E3E808-34F9-49C6-A38D-6C8E54A6D104Q47171927-F5CBDA88-B9A8-4AD5-8C84-E4A9EBFF819BQ47561695-89224E11-844D-42D2-BE00-AFC6742872FDQ48172504-1601065F-49A2-4D86-B1D8-D8DCEDC4FFB8Q48296756-244B37E0-9A6B-40A0-B9D3-43814EAE836F
P2860
Current place of monoamine oxidase inhibitors in the treatment of depression.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Current place of monoamine oxidase inhibitors in the treatment of depression.
@ast
Current place of monoamine oxidase inhibitors in the treatment of depression.
@en
Current place of monoamine oxidase inhibitors in the treatment of depression.
@nl
type
label
Current place of monoamine oxidase inhibitors in the treatment of depression.
@ast
Current place of monoamine oxidase inhibitors in the treatment of depression.
@en
Current place of monoamine oxidase inhibitors in the treatment of depression.
@nl
prefLabel
Current place of monoamine oxidase inhibitors in the treatment of depression.
@ast
Current place of monoamine oxidase inhibitors in the treatment of depression.
@en
Current place of monoamine oxidase inhibitors in the treatment of depression.
@nl
P2093
P2860
P1433
P1476
Current place of monoamine oxidase inhibitors in the treatment of depression.
@en
P2093
Kenneth I Shulman
Nathan Herrmann
Scott E Walker
P2860
P2888
P304
P356
10.1007/S40263-013-0097-3
P577
2013-10-01T00:00:00Z